Full Press Release Details
Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program.
BIIB
Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program
Key Takeaway: Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program
Price reaction · baseline $300.2 (2023-06-02 close) · clean, no other BIIB news in the window
day 0 close · peak
+0.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis